Pemvidutide is under clinical development by Altimmune and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pemvidutide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pemvidutide overview
Pemvidutide (ALT-801) is under development for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (non-alcohol related steatohepatitis or MASH or NASH), non-alcoholic fatty liver disease, type 2 diabetes and three additional unspecified indications. The drug candidate is administered subcutaneously. It is a synthetic peptide and is an analogue of oxyntomodulin. The drug candidate targets GLP-1 and glucagon receptor. It is developed based on EuPort technology.
Altimmune overview
Altimmune is a clinical-stage biopharmaceutical company that develops peptide-based therapeutics for obesity and liver diseases. The company’s pipeline products include Pemvidutide, a glucagon receptor to treat obesity and metabolic dysfunction-associated steatohepatitis (MASH). Altimmune operates under the brands NasoVAX, HepTcell, EuPort, Densigen and RespirVec. The company through its subsidiaries operates in Australia, the UK, and the US. Altimmune is headquartered in Gaithersburg, Maryland, the US.
For a complete picture of Pemvidutide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
